Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 3/2/2017 |
| Start Date: | October 2004 |
| End Date: | April 2006 |
This is a 28-week extension to a study of the safety and effectiveness of three doses of
vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose
levels in people with type 2 diabetes who have not been previously treated with drug therapy
to lower their blood sugar. The purpose of the extension study is to gather long-term safety
and efficacy data for vildagliptin in people with type 2 diabetes.
vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose
levels in people with type 2 diabetes who have not been previously treated with drug therapy
to lower their blood sugar. The purpose of the extension study is to gather long-term safety
and efficacy data for vildagliptin in people with type 2 diabetes.
Inclusion Criteria:
- Only patients successfully completing study CLAF237A2301 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion Criteria:
- Premature discontinuation from study CLAF237A2301
- Other protocol-defined exclusion criteria may apply
We found this trial at
1
site
Click here to add this to my saved trials
